Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab in Treatment‑Naive CLL
jRCT2051250016Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sonrotoclax and zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started Oct 2024; status: active, not recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2051250016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250016.